Lung Cancer

Alexander Drilon, MD, discusses the safety profile of brigatinib in ALK-positive non­–small cell lung cancer.

During an OncLive Peer Exchange program, an international panel of lung cancer experts provided perspective on key findings regarding various immune checkpoint inhibitor (ICI) combinations and data concerning potential biomarkers of response to ICIs in non–small cell lung cancer.

Ashish Saxena, MD, PhD, discusses the importance of biomarker testing for stage IV ALK-positive non–small cell lung cancer.

The combination of pembrolizumab and chemotherapy improved progression-free survival compared with chemotherapy alone as a first-line treatment for patients with extensive-stage small cell lung cancer.

Kaushal Parikh, MD, MBBS, reflects on pivotal lung cancer data shared at recent major oncology meetings.

Poziotinib did not meet its primary endpoint of overall response rate in patients with previously treated EGFR-mutant non–small cell lung cancer who have exon 20 insertion mutations.

Julia Rotow, MD, discusses the safety profile of brigatinib in ALK-positive non–small cell lung cancer.

Thomas E. Stinchcombe, MD, discusses remaining challenges in ALK-positive non­–small cell lung cancer.

Nabil P. Rizk, MD, MS, MPH, discusses the role of anatomic surgical resection in nonmetastatic lung cancer.

Benjamin P. Levy, MD, discusses treatment options for patients with oncogenic-driven non–small cell lung cancer.